Type:Injection
Generic Name:Tenecteplase
Manufacturer:Radiant Pharmaceuticals Ltd.
Price:৳64500.00
Acute myocardial infarction
IV Preparation Add 10 mL SWI to a 50 mg vial using TwinPak® device directing stream of diluent into powder. If foaming (usually slight) occurs, leave vial undisturbed for several minutes to allow dissipation of any large bubbles. Gently swirl (do not shake) until contents are completely dissolved.
Intravenous Acute myocardial infarction Adult: 30-50 mg as a single bolus dose over 5-10 sec as soon as possible after the onset of symptoms. The dose is based on body weight. Max: 50mg. Administer ASAP (within 30 minutes) after onset of acute MI 30-50 mg IV bolus over 5 sec once (based on weight) <60 kg: 30 mg 60-70 kg: 35 mg 70-80 kg: 40 mg 80-90 kg: 45 mg >90 kg: 50 mg
Patients at risk of cerebral bleeding including severe hypertension, history of stroke, intracranial or intraspinal surgery or trauma within 2 mth, arteriovenous malformation or aneurysm, cerebral neoplasm. Haemorrhage or known bleeding diathesis.
Tenecteplase is a biosynthetic form of the enzyme human tissue-type plasminogen activator (t-PA). It is a fibrin-specific thrombolytic, converts plasminogen to plasmin, a proteolytic enzyme that has fibrinolytic effects.
Patients with increased risk of bleeding. Recent history of GI or genitourinary bleed, recent major surgery, previous puncture of noncompressible vessels, hypertension (>180/110 mm Hg), high risk of left heart thrombus, acute pericarditis, subacute bacterial endocarditis, coagulation defects, invasive procedures, haemorrhagic ophthalmic conditions. Elderly, pregnancy and lactation. Severe hepatic impairment. Lactation: not known whether drug crosses into breast milk, nursing not a priority in AMI
>10% Minor bleeding (22%) Frequency Not Defined Reperfusion arrhythmias MI Fever Nausea Vomiting Cholesterol embolization Allergic reaction
Increased risk of haemorrhage with heparin, oral anticoagulants, antiplatelet drugs and other drugs that can affect platelet function.